Recently, it has been reported that a mutation in the RPL18 protein acts as a neo-epitope, eliciting a strong reaction from endogenous CD8 T cell responses in colorectal cancer mouse models; this could identify the mutant form of RPL18 as a potential target of immunotherapeutic strategies in CRC [53]. This evidence concerns the gene RPL18 and colorectal cancer.